- Investor's Business Daily•2 days ago
Puma stock rocketed to an eight-month high Thursday after the FDA approved its new drug application for a breast cancer treatment drug.
- Benzinga•2 days ago
Credit Suisse Has increased its target price for Puma Biotechnology, Inc (NYSE: PBYI ) from $54 to $111, maintaining an Outperform Rating. The increased price target is based on the firm's greater sales ...
- 24/7 Wall St.•2 days ago
Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now shares are being pushed ...
Puma Biotechnology, Inc. (PBYI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||68.50 x 100|
|Ask||69.10 x 1000|
|Day's Range||66.06 - 69.51|
|52wk Range||19.74 - 94.93|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.50|
|Avg Vol (3m)||840,954|
|Dividend & Yield||N/A (N/A)|